Ignite Creation Date:
2024-05-06 @ 6:06 PM
Last Modification Date:
2024-10-26 @ 2:41 PM
Study NCT ID:
NCT05546125
Status:
COMPLETED
Last Update Posted:
2023-04-18
First Post:
2022-08-30
Brief Title:
a Non-interventional Study of Sildenafil in the Treatment of Pulmonary Arterial Hypertension PAH in Adults From China
Sponsor:
Pfizer Pharmaceuticals Ltd
Organization:
Viatris Inc
Study Overview
Official Title:
A Non-interventional Study to Further Characterize the Safety and Effectiveness of Sildenafil in the Treatment of Pulmonary Arterial Hypertension PAH in Adults From China in a Real World Setting
Status:
COMPLETED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This observational study will involve analysis of data collected by the National Rare Disease Registry or medical records The study will describe outcomes only in PAHPulmonary arterial hypertension patients treated with sildenafil there will be no comparison with another treatment group
Approximately 100 adults with PAH will be recruited in China hospitals This NISnon-interventional study data will be recorded by a physician in the medical records during the patients clinical visits and in the electronic Case Report Forms CRF
Approximately 100 adults with PAH will be recruited in China hospitals This NISnon-interventional study data will be recorded by a physician in the medical records during the patients clinical visits and in the electronic Case Report Forms CRF
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None